LMC Diabetes & Endocrinology Ltd.
Quick facts
Marketed products
- 150% bolus insulin correction
- Basal insulin glargine and lixisenatide
- SGLT2 inhibitor and DPP-4 inhibitor · Diabetes
This combination drug lowers blood glucose by blocking kidney glucose reabsorption (SGLT2 inhibitor) and slowing incretin hormone breakdown (DPP-4 inhibitor).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: